LYCOS RETRIEVER 
Zyprexa: Companies
built 656 days ago
Eli Lilly and Company responded to two recent court rulings by the Canadian Federal Court and the German Patent Court that could result in the entry of generic olanzapine (Zyprexa) into the Canadian and German markets. Lilly believes these decisions are deeply flawed and are inconsistent with both the evidence presented at trial and with the legal principles that the company believes apply. The company plans to appeal both decisions. While the courts’ decisions may result in generic olanzapine being marketed in Canada and Germany, in both cases, should Lilly prevail on appeal, it would be entitled to damages.
Source:
A Warsaw, Poland man has named Eli Lilly and Co. the target of a lawsuit because he claims the company's Zyprexa drug gave him diabetes and other health problems. The company has asked US courts to consolidate all pending cases into one lawsuit. The battle rages on in the courts.
Source:
To "change the bipolar treatment paradigm" was seen as a major opportunity by the company, one that had "huge potential for (sic) increase in sales/value to Zyprexa and Lilly," according to the 1997 document. Weight gain was identified as one weakness of the drug, as was its cost relative to Lithium and Depakote. Zyprexa, at the time, cost on the order of ten times as much as a comparable dosage of Lithium.
Source:
Experts say that a letter sent to Eli Lilly & Co. in March by the Food and Drug Administration could mean even more lawsuits for the company over its antipsychotic drug Zyprexa. Lilly has paid more than $1.2 billion to settle roughly 29,000 claims that the drug could cause diabetes, weight gain and pancreatic infections.
Source:
Lilly has settled roughly 28,500 product-liability claims involving Zyprexa over the past two years. In June 2005, the company settled 8,000 claims for $690 million. This past January, it settled more than 18,000 for roughly $500 million.
Source:
The large pharmaceutical company Eli Lilly has been the target of numerous lawsuits due to the severe life-threatening side effects of its popular atypical antipsychotic drug Zyprexa. These lawsuits claim Lilly had prior knowledge about the potential link between Zyprexa and diabetes, but either underscored the link or dismissed it entirely.
Source:
MORE ABOUT
Companies